CNAT News and Press, Conatus Pharmaceuticals From 05/02/19

Conatus Pharmaceuticals (NASDAQ: CNAT ): Q1 GAAP EPS of -$0.14 misses by $0.02 . Revenue of $7M (-28.1% Y/Y) misses by $1.26M . Press Release More news on: Conatus Pharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news, ,

SAN DIEGO, May 02, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the first quarter ended March 31, 2019, and provided updates on its development programs. Program Updates The company is currently conducting two double-blind, ...

SAN DIEGO, April 30, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced a new publication 1 in Hepatology Communications detailing results following seven-day treatment with emricasan, the company’s first-in-class pan-caspase inhibitor, in rats...

Gainers : Fibrocell Science (NASDAQ: FCSC ) +52% . Bio-Path Holdings (NASDAQ: BPTH ) +40% . Vectrus (NYSE: VEC ) +27% . Electronics for Imaging (NASDAQ: EFII ) +27% .  SSLJ.com (NASDAQ: SSLJ ) +22% . ATA (NASDAQ: ATAI ) +21% . Advanced Disposal Services (NYSE: ADSW ) +19% . Amy...

Conatus Pharmaceuticals ( CNAT -27.2% ) slumps on double normal volume in reaction to results from a Phase 2 clinical trial, ENCORE-PH , evaluating emricasan in NASH patients with cirrhosis and severe portal hypertension. The data were presented at The International Liver Congress in Vi...

SAN DIEGO, April 15, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today that the company’s late-breaker oral presentation at The International Liver Congress™ 2019, the Annual Meeting of the European Association for the Study of the Liver (EAS...

Most developers of therapies to treat nonalcoholic steatohepatitis (NASH) are under modest pressure as investors remain unimpressed with the initial announcements from The International Liver Congress in Vienna. More news on: Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Enanta P...

The following slide deck was published by Conatus Pharmaceuticals Inc. in conjunction with this Read more ...

Market Assessment Novartis AG ( NVS ) is a Swiss (Basel, Switzerland) multi-billion biopharmaceutical company with a market cap of $217 billion and a broad therapeutic portfolio that encompasses many facets of biomedical science, including immunology, oncology, respiratory, neuroscience, o...

Author’s note: I am grateful to Dr. Pascaline Clerc, U.S Campaign Manager, The National Education Program. Introduction 2019, designated as the year of NASH in the biotech industry, was the year to demonstrate the clinical achievements in NASH therapeutics. In the beginning of...